| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2007;38:791.)
© 2007 American Heart Association, Inc.
New Approaches to Clinical Trials in Neuroprotection: Introduction |
From the University of California San Diego, La Jolla, Calif.
Correspondence to Justin A. Zivin, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093-0624. E-mail jzivin{at}ucsd.edu
Abstract
There have been numerous failures in the field of acute stroke therapy over many years, but the first large clinical trial showing preliminary indications of efficacy and safety of a neuroprotective drug, NXY-059, has now been fully reported. If confirmed, it will mean that a second therapy for acute stroke has been identified and neuroprotective drug development as a class can proceed. Additionally, a new class of drugs, HMG CoA-reductase inhibitors (statins), specifically high-dose atorvastatin, has been shown to be safe and effective for secondary stroke prevention. This drug should now become a regular part of stroke patient care.
Key Words: acute Rx acute stroke free radicals prevention statins
This article has been cited by other articles:
![]() |
R. C. Bucelli, E. A. Gonsiorek, W.-Y. Kim, D. Bruun, R. A. Rabin, D. Higgins, and P. J. Lein Statins Decrease Expression of the Proinflammatory Neuropeptides Calcitonin Gene-Related Peptide and Substance P in Sensory Neurons J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1172 - 1180. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |